TGFB1 and neoplasm: Surprisingly, the α-TGFβ antibody given as monotherapy showed significantly better anti-tumor efficacy than α-PD-1 monotherapy for CCK168 tumors (Fig. 3 b, c), with more than 20% of established CCK168 tumors showing durable CR after α-TGFβ monotherapy (Fig. 3c).